

Steve Y Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8485658/publications.pdf>

Version: 2024-02-01

36
papers

2,040
citations

516710

16
h-index

414414

32
g-index

36
all docs

36
docs citations

36
times ranked

2409
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2015, 17, 565-574.	2.6	378
2	Biodistribution, Tumor Detection, and Radiation Dosimetry of ¹⁸ F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1883-1891.	5.0	264
3	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	2.6	202
4	¹⁸ F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	5.0	180
5	Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. <i>Clinical Cancer Research</i> , 2021, 27, 3674-3682.	7.0	179
6	Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 5-15.	1.0	165
7	Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2015, 29, 877-882.	2.2	152
8	Comparison of Prostate-Specific Membrane Antigen-Based ¹⁸ F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	5.0	111
9	Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. <i>Pediatric Radiology</i> , 2019, 49, 1545-1564.	2.0	71
10	[124I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. <i>Nuclear Medicine and Biology</i> , 2016, 43, 273-279.	0.6	47
11	Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 187, 39-48.	2.5	44
12	Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAH): Methodology statement. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26421.	1.5	35
13	Uptake of [18F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies. <i>Tomography</i> , 2015, 1, 81-84.	1.8	31
14	Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. <i>Radiology</i> , 2018, 287, 303-312.	7.3	25
15	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 518-531.	4.6	25
16	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted ¹⁸ F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1430-1437.	5.0	24
17	PET Imaging for Breast Cancer. <i>Radiologic Clinics of North America</i> , 2021, 59, 725-735.	1.8	15
18	Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG PET parameter analysis in a subgroup from COG AHOD0031. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29212.	1.5	13

#	ARTICLE	IF	CITATIONS
19	Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 989-998.	6.4	12
20	In vitro evaluation of adenosine 5'-monophosphate as an imaging agent of tumor metabolism. Journal of Nuclear Medicine, 2006, 47, 837-45.	5.0	11
21	The Role of PET in the Evaluation of Musculoskeletal Infections. Seminars in Musculoskeletal Radiology, 2014, 18, 166-174.	0.7	8
22	A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 458-463.	0.8	8
23	US Trainee and Faculty Perspectives on Exposure to Nuclear Medicine/Molecular Imaging During Medical School. Current Problems in Diagnostic Radiology, 2021, 50, 585-591.	1.4	7
24	Liver involvement in pediatric Hodgkin lymphoma: A systematic review by an international collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAH). Pediatric Blood and Cancer, 2020, 67, e28365.	1.5	5
25	Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).. Journal of Clinical Oncology, 2022, 40, 7504-7504.	1.6	5
26	Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis. Blood, 0, , .	1.4	4
27	Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma. EJNMMI Physics, 2017, 4, 22.	2.7	3
28	Proposed Criteria Positions PSMA PET for the Future. Journal of Nuclear Medicine, 2018, 59, 466-468.	5.0	3
29	To Hold or Not to Hold Metformin for FDG PET Scans: That Is the Question. Radiology, 2018, 289, 426-427.	7.3	3
30	Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2022, 112, 890-900.	0.8	3
31	PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).. Journal of Clinical Oncology, 2021, 39, TPS267-TPS267.	1.6	2
32	18f-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). A Preliminary Retrospective Analysis of Children's Oncology Group (COG) AHOD0031. Blood, 2012, 120, 1530-1530.	1.4	2
33	Amyloid deposition on positron emission tomography correlates with severity of perioperative delirium: a case-control pilot study. British Journal of Anaesthesia, 2022, , .	3.4	2
34	Clinical Translation of Molecular Imaging Probes. , 2012, , 1041-1065.		1
35	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)â€™A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.. Journal of Clinical Oncology, 2021, 39, 33-33.	1.6	0
36	Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.. Journal of Clinical Oncology, 2021, 39, 74-74.	1.6	0